Search results
Showing 1 to 15 of 49 results for alopecia
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.
Capecitabine for the treatment of advanced gastric cancer (TA191)
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Past technology appraisal appeals and decisions
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.